(Q35747877)

10 August 2017

1 reference

title

Mitoxantrone: a review of its use in multiple sclerosis (English)

1 reference

10 August 2017

0 references

1

Lesley J Scott

1 reference

10 August 2017

2

David P Figgitt

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

18

1 reference

10 August 2017

6

1 reference

10 August 2017

379-396

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200418060-00010

10 August 2017

0 references

cites work

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

New treatments for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

Recent Advances. Neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200418060-00010

Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats

21 January 2018

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function

1 reference

12 December 2020

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects

1 reference

12 December 2020

Outcomes assessment of drug treatment in multiple sclerosis clinical trials

1 reference

12 December 2020

Immunotherapy in multiple sclerosis, Part 2.

1 reference

12 December 2020

Disposition of mitoxantrone in cancer patients

1 reference

12 December 2020

Treatment of multiple sclerosis with mitoxantrone

1 reference

12 December 2020

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone

1 reference

12 December 2020

New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites

1 reference

12 December 2020

What is new in the treatment of multiple sclerosis?

1 reference

12 December 2020

Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.

1 reference

12 December 2020

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia

1 reference

12 December 2020

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer

1 reference

12 December 2020

Identification of human urinary mitoxantrone metabolites

1 reference

12 December 2020

Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis

1 reference

12 December 2020

Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis

1 reference

12 December 2020

Contemporary immunomodulatory therapy for multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Suppression of demyelination by mitoxantrone

1 reference

12 December 2020

Why treat early multiple sclerosis patients?

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

1 reference

12 December 2020

Clinical safety and tolerance of mitoxantrone

1 reference

12 December 2020

1 reference

12 December 2020

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Inhibition of the induction of alloreactivity with mitoxantrone

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

The treatment of multiple sclerosis: current and future.

1 reference

12 December 2020

The clinical pharmacology of mitozantrone

1 reference

12 December 2020

Natural history of multiple sclerosis

1 reference

12 December 2020

Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity

1 reference

12 December 2020

Disease-modifying Therapies for Multiple Sclerosis.

1 reference

12 December 2020

Pharmacokinetics and metabolism of mitoxantrone. A review

1 reference

12 December 2020

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1 reference

12 December 2020

Delayed, relapsing experimental allergic encephalomyelitis in mice

1 reference

12 December 2020

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues

1 reference

12 December 2020

MRI in the diagnosis and management of multiple sclerosis

1 reference

12 December 2020

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

1 reference

12 December 2020

Multiple sclerosis: clinical presentation, diagnosis and treatment.

1 reference

12 December 2020

Human autopsy tissue concentrations of mitoxantrone.

1 reference

12 December 2020

Current immunotherapy for demyelinating diseases

1 reference

12 December 2020

Choosing drug therapy for multiple sclerosis. An update.

1 reference

12 December 2020

Pharmacology of mitoxantrone in cancer patients

1 reference

12 December 2020

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Emerging treatments in multiple sclerosis

1 reference

12 December 2020

Management of multiple sclerosis

1 reference

12 December 2020

Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone

1 reference

12 December 2020

Considerations in the treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Relapsing-remitting multiple sclerosis: what is the potential for combination therapy?

1 reference

12 December 2020

Multiple sclerosis: the importance of early recognition and treatment.

1 reference

12 December 2020

A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

1 reference

12 December 2020

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management

1 reference

12 December 2020

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

1 reference

12 December 2020

Early intervention in multiple sclerosis : better outcomes for patients and society?

1 reference

12 December 2020

10.2165/00023210-200418060-00010

Identifiers

DOI

1 reference

PubMed ID

15089110

Dimensions Publication ID

10 August 2017

0 references

1 reference

PubMed ID

15089110